[FOXD2-AS1 is corelated with clinicopathological parameter of laryngeal carcinoma and promote cancer cell proliferation].

Objective: To investigate the expression and clinical significance of long non-coding RNA FOXD2-AS1 in laryngeal squamous cell carcinoma and its effect on cancer cell proliferation. Method: Real-time quantitative polymerase chain reaction(RT-qPCR) was used to detect the expression of FOXD2-AS1 in 85 cases of laryngeal carcinoma. One-way ANOVA was used to determine relationships between its expression and clinicopathological parameters of laryngeal carcinoma. The prognostic significance of FOXD2-AS1 in head and neck cancer was explored using bioinformatics technology. SiRNA was used to interfere the expression of FOXD2-AS1 in TU686 laryngeal carcinoma cells. MTT and clonal formation assay were used to investigate the biological effect of FOXD2-AS1. MicroRNA binding to FOXD2-AS1 was investigated using double luciferase assay. Result: The expression of FOXD2-AS1 in laryngeal cancer tissues was significantly higher than that in normal tissues(t=10.012, P<0.05), and was associated with T staging of laryngeal cancer(χ=6.41, P=0.016). There were no relationships between FOXD2-AS1 expression and age, sex, smoking history, primary site of tumor and lymph node metastasis(N staging). Survival analysis of head and neck tumors in the TCGA database using GEPIA showed poor prognosis in patients with high FOXD2-AS1 expression(P=0.048). Suppressing FOXD2-AS1 via siRNA in TU686 cells decreased clonal formation ability(t=8.053, P<0.05) and MTT assay confirmed that interference of FOXD2-AS1 down regulated proliferation activity of TU686 cells(t=9.337, P<0.05). Double luciferase assay showed that FOXD2-AS1 could directly bind to miR-206, thus inhibiting the expression of miR-206. Further MTT assay indicated that inhibiting miR-206 attenuated the suppressing effect of si-FOXD2-AS1 on the proliferation of TU686 cells.
Conclusion: FOXD2-AS1 is corelated with clinicopathological parameter of laryngeal squamous cell carcinoma and promotes cancer cell proliferation through targeting miR-206. Copyright© by the Editorial Department of Journal of Clinical Otorhinolaryngology Head and Neck Surgery.